Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-07-19
2005-07-19
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S282000, C514S331000, C514S592000, C514S647000
Reexamination Certificate
active
06919310
ABSTRACT:
The invention provides an improved method of treating a human suffering from one or more conditions included within the Coronary Heart Disease Risk Factor (CHDRF) syndrome. The method includes administering, by a pharmaceutically effective mode, a drug composition having an opioidergic agent including an opiate antagonist, opiate having μ-agonist activity or combination thereof, and an insulin secretagogue.
REFERENCES:
patent: 4055175 (1977-10-01), Clemens et al.
patent: 4217353 (1980-08-01), Smith, Jr.
patent: 4272540 (1981-06-01), Razdan et al.
patent: 4451470 (1984-05-01), Ganti
patent: 4478840 (1984-10-01), Smith, Jr.
patent: 4511570 (1985-04-01), Tuttle
patent: 4619936 (1986-10-01), Balkanyi et al.
patent: 4760069 (1988-07-01), Rzeszotarski et al.
patent: 4857533 (1989-08-01), Sherman et al.
patent: 4863928 (1989-09-01), Atkinson et al.
patent: 4877791 (1989-10-01), Sherman
patent: 4880813 (1989-11-01), Frost
patent: 4882335 (1989-11-01), Sinclair
patent: 4888346 (1989-12-01), Bihari et al.
patent: 4994466 (1991-02-01), Sherman
patent: 5013739 (1991-05-01), Bihari et al.
patent: 5086058 (1992-02-01), Sinclair et al.
patent: 5356900 (1994-10-01), Bihari et al.
patent: 5468755 (1995-11-01), Cincotta et al.
patent: 5578645 (1996-11-01), Askanazi et al.
patent: 5626860 (1997-05-01), Cincotta et al.
patent: 5727570 (1998-03-01), Clemens
patent: 5830895 (1998-11-01), Cincotta et al.
patent: 5863555 (1999-01-01), Heiber et al.
patent: 5878750 (1999-03-01), Clemens
patent: 6026817 (2000-02-01), Clemens
patent: 6159500 (2000-12-01), Demopoulos et al.
patent: 6190691 (2001-02-01), Mak
patent: 6262062 (2001-07-01), Clemens
patent: 6528520 (2003-03-01), Clemens
patent: 2003/0036546 (2003-02-01), Clemens
patent: 2003/0105121 (2003-06-01), Bihari
patent: 0 078 434 (1983-05-01), None
patent: 0 541 192 (1993-05-01), None
patent: 2045758 (1980-11-01), None
patent: WO 97/18781 (1997-05-01), None
patent: WO 97/35608 (1997-10-01), None
patent: WO 99/04795 (1999-02-01), None
patent: WO 99/59997 (1999-11-01), None
patent: WO 02/100390 (2002-12-01), None
patent: WO 03/026635 (2003-04-01), None
Cole, Evaluation of Chronic Opioid Receptor Antagonist Effects Upon Weight and Intake Measures in Lean and Obese Zucker Rats, Peptides, vol. 18, No. 8, 1997 pp. 1201-1207.
Shaw, The Effect of the Opiod Antagonist LY255582 on Body Weight of the Obese Zucker Rat, International Journal of Obesity, vol. 15, No. 6, Jun. 1991, pp. 387-395.
Givens, et al., Reduction of Hyperinsulinemia and Insulin Resistance by Opiate Receptor Blockade in the Polycystic Ovary Syndrome with Acanthosis Nigricans, Journal of Clinical Endocrinology and Metabolism, New York NY, vol. 64, No. 2, Feb. 1987, pp. 377-382.
Wexler, et al., Anti-Opiate (Naloxone) Suppression of Cushingoid Degenerative Changes in Obese/SHR, International Journal of Obesity, Newman Publishing London, vol. 9, No. 2, 1985 pp. 77-91.
McIntosh, et al., The Effects of Opioid Receptor Selective Antagonists and Agonists Following Coronary Artery Occlusion in Anaesthetised Rats, Journal of Molecular and Cellular Cardiology, vol. 22, No. Suppl 3, Oct. 1990 (1990-10) p. S72.
Pearce, et al., Effects of X-Opioid and AVP-V1 Recetor Antagonists on the Compensatory Hemodynamic Responses of Anesthetized Rats Following Acute Hemorrhage, Canadian Journal of Physiology and Pharmacology Ottawa, Ont, CA, vol. 70, No. 5, 1992, pp. A18-A19.
Garris, Nalmefene, An Opiate Antagonist, Effectively Modulates Insulin Receptor Binding in the Peripheral Tissues of C57BL/KSJ Mice, Medical Science Research, Elsevier Applied Science, Barking, GB, vol. 16, No. 6, 1988, pp. 301-302.
Drolet, et al., Endogenous Opioids Tonically Inhibit the Depressor Neurones in the Caudal Ventrolateral Medulla of Rabbits: Mediation through Delta and Kappa-Receptors, Neuropharmacology, Pergamon Press, Oxford, GB, vol. 30, No. 4, Apr. 1991 pp. 383-390.
McLauglin, et al., Influence of Nalmefene on Energy Balance and Glucose Regulation in Zucker Rats, Physiology and Behavior, Elsevier Science Ltd., Oxford, GB, vol. 37, No. 6, 1986, pp. 899-908.
McLaughlin, et al., Nalmefene Decreases Meal Size, Food and Water Intake and Weight Gain in Zucker Rats, Pharmacology Biochemistry and Behavior, Elsevier, US, vol. 19, No. 2, Aug. 1993, pp. 235-240.
McIntosh, et al., Effects of Selective Opioid Receptor Agonists and Antagonists During Myocardial Ischaemia, European Journal of Pharmacology, Amsterdam, NL, vol. 210, No. 1 Jan. 7, 1992, pp. 37-44.
Wexler, Naloxone Ameliorates the Pathophysiologic Changes which Lead to and Attend an Acute Stroke in Stroke-Prone/SHR, Stroke, American Heart Association, Dallas, TX, vol. 15, No. 4, Jan. 1984, pp. 630-634.
Giugliano, et al., Sensitivity to Beta-Endorphin as a Cause of Human Obesity, Metabolism, Clinical and Experimental, W.B. Saunders Co., Philadelphia, PA, vol. 36, No. 10, Oct. 1987, pp. 974-978.
Caldwell, et al., Actions of the Opioid Antagonist, Nalmefene, and Congeners on Reperfusion Cardiac Arrhythmias and Regional Left Coronary Blood Flow, Pharmacology, vol. 41, No. 3, 1990, pp. 161-166.
Bernardi, et al., Endogenous Opioid System in Acute Myocardial Infarction, Journal of Molecular and Cellular Cardiology, vol. 16, No. Suppl 2, 1984, p. 53.
Imai, et al., Effects of Opioid Antagonism in Congestive Heart Failure, Circulation (72, no. 4, Pt. 2, 1985) p. 248.
Levine, et al., Effect of Chronic Administration of Morphine and Nalmefene on Food Intake and Body Weight in Diabetic and Control Rats, Society for Neuroscience Abstracts, vol. 11, No. 1, 1985, p. 55.
Simpkins, et al., Efects of the Narcotic Antagonist Nalmefene on Spontaneous and Insulin-Induced Food Intake and Body Weight Gain in Male Rats, Society for Neuroscience Abstracts, vol. 11, No. 1, 1985, p. 59.
McLaughlin, et al., Glucose Insulin Food Intake and Body Weight Responses of Zucker Rats to Nalmefene and Opiate Antagonist, Diabetes Research and Clinical Practice, No. SUPPL 1, 1985, p. S372.
Szilagyi, “Psychosocial Stress Elevates Blood Pressure Via an Opioid Dependent Mechanism in Normotensive Rats, Clinical and Experimental Hypertension,” Part A, Theory and Practice, U.S. 1991, vol. 13, No. 8, 1991, pp. 1383-1394.
Kurtz B. R. et al., “Nalmefene an Orally Active Opiate Antagonist Reduces Insulin Resistance and Caloric Intake in Obese Women with Polycystic Ovaries and Acanthosis Nigricans”, Clinical Research, vol. 33, No. 2 Part 1, 1985, p. 615A.
Arias A. et al., “Influence of Selective Agonist K Peripheral ICI-204448 (ICI) on Blood Pressure of Rats Pretreated with Clonidine (CLO)” Methods and Findings in Experimental and Clinical Pharmacology, Prous, Barcelona, ES, vol. 19, No. Suppl. A, Nov. 1997, p. 92.
McCubbin J. A. et al., “Opiodergic Inhibition of Circulatory and Endocrine Stress Responses in Cynomolgus Monkeys: A Preliminary Study” Psychosomatic Medicine, Elsevier, New York NY, US, vol. 55, no. 1, Jan. 1993, pp. 23-28.
Spanagel R. et al., “Evidence That Nor-Binaltorphimine Can Function as an Antagonist at Multiple Opioid Receptor Subtypes” European Journal of Pharmacology, Amsterdam, NL, vol. 264, No. 2, Oct. 24, 1994 (Oct. 24, 1994), pp. 157-162.
Database Medline Online! US National Library of Medicine (NLM), Bethesda, MD, US; Nov. 26, 1990 (Nov. 26, 1990) Levine, A. S. et al. “Nor-binaltorphimine decreases deprivation and opioid-induced feeding.” Database accession No. NLM1963567 & Brain Research, Netherlands Nov. 26, 1990, vol. 534, No. 1-2, pp. 60-64.
Database Embase (Online), Elsevier Science Publishers, Amsterdam, NL; 1987, Giugliano, D. et al. “(beta)-Endorphin and Islet Hormone Release in Type-2 Diabetes Mellitus. The effects of normoglycemia, enkephalin, naloxone and somatostatin”, Database accession No. EMB-1988087121, XP002257952 abstract, & Diabete et Metabolisme, 1987 France, vol. 13, No. 6, 1987, pp. 618-624, ISSN: 0338-1684.
Khawaja, X. Z., et al., “Increased Sensitivity to Insulin-Releasing and Glucoregulatory Effects of Dynorphin A1-13 and U 50488h in ob/ob versus lean miceȁ
CPD, LLC
Henley III Raymond J.
Michael & Best & Friedrich LLP
LandOfFree
Method of treating the syndrome of coronary heart disease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating the syndrome of coronary heart disease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating the syndrome of coronary heart disease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3372774